Data highlights that Aspect’s bioprinted liver tissues can rescue immune-competent mice from acute liver failure
Vancouver, BC, Canada - November 2, 2022 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, will present new preclinical data on its bioprinted liver tissue therapeutic platform at the The Liver Meeting® 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), held in Washington, DC from November 4-8, 2022. Presented data will highlight that Aspect’s bioprinted liver tissues are capable of rescuing immune-competent mice from carbon tetrachloride (CCl4)-induced liver failure without the need for immune suppression.
“At Aspect, we are deeply committed to creating novel tissue therapeutics capable of tackling the most elusive diseases,” said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. “We believe that our bioprinted liver tissue therapeutic platform holds immense potential for replacing lost hepatic function in people living with acquired and congenital liver diseases. We are encouraged by our most recent preclinical data demonstrating the potential for this platform to provide a bridge to recovery or transplantation for individuals with acute and acute-on-chronic liver failure.”
Poster Presentation Details:
- Title: Bioprinted Liver Tissues Improve Survival in a Mouse Model of Acute Liver Failure
- Poster #: 5030 | Abstract #: 39043
- Date: Monday, November 7, 2022
- Time: 1:00-2:00pm
About The Liver Meeting®
Hosted by the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting® brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company creating bioprinted tissue therapeutics to transform how we treat disease. Aspect is combining its proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create a pipeline of allogeneic tissues that replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at www.aspectbiosystems.com.